IPI-9119

• UNSPSC Description:

  IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC50 of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models[1][2].

• Target Antigen:

  Fatty Acid Synthase (FASN)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ipi-9119.html

• Purity:

  99.24

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)C1=CC=C(N(C(N2N=NN(C3=C(F)C=CC=C3F)C2=O)=O)C(C)C)C(OC4=CC=CC=C4)=C1

• Molecular Weight:

  495.43

• References & Citations:

  [1]Giorgia Zadra, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640.|[2]Erin Broph, et al. Abstract 1891: Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1346564-56-4